Subscribe To
VPHIF / Valeo Pharma posts 128% increase in revenue in first quarter boosted by its three lead products
VPHIF News
By Proactive Investors
October 5, 2023
Valeo Pharma CEO credits Enerzair for strong position on Canada's top-growing companies list
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe an more_horizontal
By Proactive Investors
October 4, 2023
Valeo Pharma secures spot on Canada's top-growing companies list
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) highlighted to investors that it has placed at spot 151 on the Globe and Mail's Report on Business annual lis more_horizontal
By Proactive Investors
September 14, 2023
Valeo Pharma reports record quarterly revenue or strong demand for Enerzair and Atectura therapies
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported its seventh consecutive rise in revenues to a quarterly record due to strong growth in its Enerz more_horizontal
By Proactive Investors
September 1, 2023
Valeo Pharma raises funds totalling $4.5M
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has closed a non-brokered private placement offering, raising gross proceeds of $3.92 million. The company a more_horizontal
By Proactive Investors
June 22, 2023
Valeo Pharma bolsters board with two new directors
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Tamara Close and Didier Leconte have both joined its board of directors, noting that following the appo more_horizontal
By Proactive Investors
June 14, 2023
Valeo Pharma reports record quarterly revenues
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record quarterly revenues of $13.6 million for its second quarter ending April 30, 2023, repr more_horizontal
By Proactive Investors
May 25, 2023
Valeo Pharma expects 2Q revenues to set quarterly record
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it expects revenues in the second quarter to exceed $13.5 million, a quarterly record, with operating ex more_horizontal
By Proactive Investors
March 16, 2023
Valeo Pharma reports record 1Q revenue and gross profit buoyed by new products and higher market share
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said its revenue for the first quarter ended January 31, 2023, rose by 210% to a record $13.2 million, up fro more_horizontal